GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Clinitech Laboratory Ltd

Clinitech Laboratory Board Approves Q2 FY27 Un-Audited Financial Results

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 13 Nov 2026, 01:25 PM IST  ·  BSE ID: cb9f3dd6-47e1-4e81-b32a-a0a3f3ae861e
View Original BSE Filing (PDF)
💡
In Simple Terms
Clinitech Laboratory's board approved its latest financial results for the last six months and reviewed its IPO funds use.
🤖 AI Summary
  • Board approved un-audited standalone and consolidated financial results for the half year ended September 30, 2026 (Q2 FY27).
  • Limited Review Report from statutory auditors for the half year ended September 30, 2026, was enclosed.
  • Utilization of IPO proceeds was considered and noted by the Board.
  • Internal Audit report for the half year ended September 30, 2026, was taken note of.
  • A certificate on issue proceeds utilization, certified by Statutory Auditor, was enclosed as per NSE circular.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this board meeting outcome.
👤
Who Is Affected
All shareholders are informed of the completion of routine financial reporting for the half year ended September 30, 2026, which includes a review of IPO proceeds.
🔍
Management Signal
Management is signaling compliance with regulatory financial reporting requirements and diligence in reviewing IPO fund utilization and internal audits.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Review the detailed financial results once they are made publicly available.
Monitor future filings for specific details on IPO proceeds utilization.
Await Q3 FY27 financial results for subsequent performance indicators.
LOW RISK The filing is a routine board meeting outcome with no new risks identified.
💡 Investor Takeaway
The Board of Clinitech Laboratory Limited has approved the Un-Audited Standalone & Consolidated Financial Results for the half year ended September 30, 2026. The filing also confirms the Board considered the utilization of IPO proceeds and noted the Internal Audit report for the same period.
📅 Company Track Record
No previous filings or specific historical financial data for Clinitech Laboratory Ltd are available to provide comparative context for this reporting period. The company's recent listing status suggests limited public track record information.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What financial period did Clinitech Laboratory's Board approve?
The Board of Clinitech Laboratory Limited approved the Un-Audited Standalone & Consolidated Financial Results for the half year ended September 30, 2026, which is Q2 FY27.
What additional items did Clinitech Laboratory's Board consider in its meeting?
The Board considered and noted the utilization of IPO proceeds and took note of the Internal Audit report for the half year ended September 30, 2026.
Was a review conducted on Clinitech Laboratory's financial results?
Yes, the Un-Audited Standalone & Consolidated Financial Results for the half year ended September 30, 2026, were accompanied by a Limited Review Report (LRR) by the Statutory Auditors.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.